Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|March 9, 2016
Successes and Challenges California Pharmacists Have Faced in Dispensing Naloxone
Jon Roth, CEO of the California Pharmacists Association, discusses the successes and challenges California pharmacists have faced in dispensing naloxone.
Advertisement
Jon Roth, CEO of the California Pharmacists Association, discusses the successes and challenges California pharmacists have faced in dispensing naloxone.
This video was filmed at APhA's 2016 Annual Meeting in Balitmore, MD.
Advertisement
Related to this article
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
New European Respiratory Society (ERS) update makes sotatercept a strong add-on recommendation, opening a fourth pathway for pharmacists to manage.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5